| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of non-small cell lung cancer with EGFR exon 20 insertion treated with osimertinib
|
Morton-Gittens, Jamie
|
|
|
156 |
S1 |
p. S73-S74
|
artikel
|
| 2 |
Adapting lung cancer diagnostics during the Covid-19 pandemic
|
Bull, Alex
|
|
|
156 |
S1 |
p. S8
|
artikel
|
| 3 |
Adjuvant treatment: does it affect the surgical outcome of N2 non-small cell lung cancer
|
Ahmed, Hesham Ahmed
|
|
|
156 |
S1 |
p. S44
|
artikel
|
| 4 |
Altered expression of ACOX2 and other members of the peroxisome pathway in non-small cell lung cancer
|
Sui, Jane
|
|
|
156 |
S1 |
p. S2
|
artikel
|
| 5 |
Analysis of investigation and management of patients with mesothelioma in the Mid Yorkshire Hospitals NHS Trust: a 5-year retrospective study
|
Lee Evans, Hannah
|
|
|
156 |
S1 |
p. S31-S32
|
artikel
|
| 6 |
Analysis of the source of lung cancer diagnoses during 2020 COVID-19 pandemic compared with 2015-2019 in the York and Scarborough NHS Trust
|
Watchorn, Hazel
|
|
|
156 |
S1 |
p. S16
|
artikel
|
| 7 |
An audit of compliance with NOLCP in the GLH era
|
Ly, Fabrice
|
|
|
156 |
S1 |
p. S27
|
artikel
|
| 8 |
An evaluation of a newly established navigation bronchoscopy service set in a UK lung cancer centre
|
Craig, Christopher
|
|
|
156 |
S1 |
p. S26-S27
|
artikel
|
| 9 |
An evaluation of a pleural fellowship
|
Aujayeb, Avinash
|
|
|
156 |
S1 |
p. S4
|
artikel
|
| 10 |
An institution’s experience on concurrent chemoradiotherapy (CCT) in non-small cell lung Ccancer (NSCLC)
|
Choudhury, Mahbuba
|
|
|
156 |
S1 |
p. S55
|
artikel
|
| 11 |
An unusual case of ALK mutation in large-cell neuroendocrine carcinoma of lung and response to alectinib
|
Williams, Adenike
|
|
|
156 |
S1 |
p. S72
|
artikel
|
| 12 |
Anxiety and depression in lung cancer patients during Covid-19 pandemic
|
Jacob, Anitha
|
|
|
156 |
S1 |
p. S16
|
artikel
|
| 13 |
A Pilot Service Improvement Project on dietetic interventions in lung cancer patients undergoing immune checkpoint inhibitor (ICI) treatments: preliminary report
|
Bulusu, Venkata
|
|
|
156 |
S1 |
p. S49
|
artikel
|
| 14 |
A real-world analysis of 30-day post systemic anti-cancer therapy mortality in patients with small cell lung cancer
|
Carter, Louise
|
|
|
156 |
S1 |
p. S65
|
artikel
|
| 15 |
A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
|
Church, Matt
|
|
|
156 |
S1 |
p. S31
|
artikel
|
| 16 |
A re-audit of patients with malignant pleural mesothelioma (MPM) in Worcestershire Acute Hospitals NHS Trust
|
Saram, Sarah
|
|
|
156 |
S1 |
p. S30
|
artikel
|
| 17 |
Are robotic pulmonary lobectomies associated with as good nodal assessment as conventional surgery?
|
Deans, Scott
|
|
|
156 |
S1 |
p. S70
|
artikel
|
| 18 |
A retrospective audit into the prophylactic use of antibiotics in patients receiving chemotherapy for lung cancer
|
Crockett, Cathryn
|
|
|
156 |
S1 |
p. S34
|
artikel
|
| 19 |
A retrospective study of frailty risk factors in patients diagnosed with lung cancer
|
Chauhan, Meera
|
|
|
156 |
S1 |
p. S53
|
artikel
|
| 20 |
A single institution experience on concurrent chemoradiotherapy (CCT) in non-small cell lung cancer (NSCLC)
|
Choudhury, Mahbuba
|
|
|
156 |
S1 |
p. S55
|
artikel
|
| 21 |
Assessing lung toxicity with radical hypofractionated (non-SABR) radiotherapy
|
McAleese, Jonathan
|
|
|
156 |
S1 |
p. S56
|
artikel
|
| 22 |
Assessing outcomes in patients that received consolidation radiotherapy following palliative chemotherapy in patients diagnosed with extensive stage small cell lung cancer
|
Williams, Adenike
|
|
|
156 |
S1 |
p. S56-S57
|
artikel
|
| 23 |
Audit of cyclophosphamide/adriamycin/vincristine (CAV) chemotherapy use in Edinburgh Cancer Centre
|
Boh, Zhuang
|
|
|
156 |
S1 |
p. S65
|
artikel
|
| 24 |
Author index
|
|
|
|
156 |
S1 |
p. S79-S83
|
artikel
|
| 25 |
Availability of programmed death-ligand 1 (PD-L1) status in newly diagnosed, stage III, locally advanced, unresectable non-small cell lung carcinoma patients – a single institution audit
|
Tan, Ian Zing
|
|
|
156 |
S1 |
p. S35-S36
|
artikel
|
| 26 |
Best practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions
|
Gosney, John
|
|
|
156 |
S1 |
p. S34
|
artikel
|
| 27 |
Bilateral indwelling pleural catheters
|
Aujayeb, Avinash
|
|
|
156 |
S1 |
p. S66
|
artikel
|
| 28 |
Cancer therapy pneumonitis incidence, severity and management: findings from a large UK cancer centre
|
Hindocha, Sumeet
|
|
|
156 |
S1 |
p. S37
|
artikel
|
| 29 |
Can PDL-1 levels predict response to triple regimen (carboplatin + pembrolizumab+ pemetrexed) in treatment for metastatic non-small cell lung cancer – a real world outcome study
|
Saxena, Aaruni
|
|
|
156 |
S1 |
p. S37-S38
|
artikel
|
| 30 |
Case report: low risk thymoma with pleural recurrence following a 21-year latency period since thymectomy
|
Anandan, Lavanya
|
|
|
156 |
S1 |
p. S74
|
artikel
|
| 31 |
Case series of ctDNA EGFR testing for non-smoking lung cancer
|
Patterson, Daniel
|
|
|
156 |
S1 |
p. S20-S21
|
artikel
|
| 32 |
Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung)
|
Banfill, Kathryn Banfill
|
|
|
156 |
S1 |
p. S14
|
artikel
|
| 33 |
Clinical frailty scoring in lung cancer patients referred for palliative radiotherapy
|
Zarroug, Maha
|
|
|
156 |
S1 |
p. S63
|
artikel
|
| 34 |
Clinical outcomes after radical radiotherapy for lung cancer in patients with interstitial lung disease
|
Walls, Gerard
|
|
|
156 |
S1 |
p. S62-S63
|
artikel
|
| 35 |
Clinico-pathological features of MET exon 14 mutation positive NSCLC in the UK
|
Benafif, Sarah
|
|
|
156 |
S1 |
p. S46
|
artikel
|
| 36 |
Community lung health check as a screening tool for lung cancer: initial results from a Bradford pilot
|
Nayyar, Moez
|
|
|
156 |
S1 |
p. S26
|
artikel
|
| 37 |
Comparison between 1st generation EGFR tyrosine kinase inhibitor (gefitinib) versus 2nd generation (afatinib) in EGFR-mutated non-small cell lung cancers (NSCLC) – real world experience
|
Dulloo, Sean
|
|
|
156 |
S1 |
p. S42-S43
|
artikel
|
| 38 |
Comparison of immunohistochemistry and polymerase chain reaction for single gene vs multigene panel with next generation sequencing for identifying targetable mutations in non-small cell lung cancer
|
Linehan, Anna
|
|
|
156 |
S1 |
p. S43-S44
|
artikel
|
| 39 |
Complications after lung ablation: when can patients be safely discharged?
|
Warwick, Gill
|
|
|
156 |
S1 |
p. S54-S55
|
artikel
|
| 40 |
Correlation of 18F-FDG-PET/CT metabolic parameters with PD-L1 tumour proportion score (TPS) in resected non-small cell lung cancer (NSCLC)
|
Hughes, Daniel
|
|
|
156 |
S1 |
p. S3
|
artikel
|
| 41 |
Covid-19 in lung cancer patients in a DGH
|
Aujayeb, Avinash
|
|
|
156 |
S1 |
p. S7-S8
|
artikel
|
| 42 |
Day case medical thoracoscopy in a district general hospital
|
Harrison, Emily
|
|
|
156 |
S1 |
p. S4
|
artikel
|
| 43 |
Delivering bronchoscopy and respiratory diagnostic service for lung cancer during COVID-19 pandemic: a single-centre experience
|
Yeo, Sue-Lis
|
|
|
156 |
S1 |
p. S17-S18
|
artikel
|
| 44 |
Detection of tier 1 variants with circulating tumour (ct) DNA next generation sequencing (NGS) in UK non-small cell lung cancer (NSCLC) patients
|
Milner-Watts, Charlotte
|
|
|
156 |
S1 |
p. S28
|
artikel
|
| 45 |
Developing a framework for a telephone pathway for lung cancer patients receiving SACT
|
Templeton, Maureen
|
|
|
156 |
S1 |
p. S49
|
artikel
|
| 46 |
Does lung cancer screening information support informed decision-making? A systematic environmental scan review
|
Tonge, Janet
|
|
|
156 |
S1 |
p. S24-S25
|
artikel
|
| 47 |
Does the use of primary care spirometry results in patients referred with suspected lung cancer have potential to avoid delays in the lung cancer referral pathway as a result of the SARS-COV-2 pandemic?
|
Ni Chleirigh, Romy
|
|
|
156 |
S1 |
p. S13
|
artikel
|
| 48 |
Does thymic malignancy impair myasthenia gravis disease outcomes after surgical intervention: a 3-year analysis
|
Tan, Dylan
|
|
|
156 |
S1 |
p. S50
|
artikel
|
| 49 |
Editorial Board
|
|
|
|
156 |
S1 |
p. ii
|
artikel
|
| 50 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations – real world data
|
Dulloo, Sean
|
|
|
156 |
S1 |
p. S40
|
artikel
|
| 51 |
Emergency presentation of lung cancer: did it increase during the COVID-19?
|
Lupei, Cai
|
|
|
156 |
S1 |
p. S12-S13
|
artikel
|
| 52 |
Endobronchial ultrasound (EBUS) characteristics of malignant mediastinal lymph nodes
|
Mehta, Meera
|
|
|
156 |
S1 |
p. S23-S24
|
artikel
|
| 53 |
Engaging medical teams in support group recommendations
|
Abbott, Jenny
|
|
|
156 |
S1 |
p. S51-S52
|
artikel
|
| 54 |
Establishment of an ambulatory thoracoscopy service
|
Sapkal, Toshit
|
|
|
156 |
S1 |
p. S20
|
artikel
|
| 55 |
Evaluation of telephone consultations for follow up lung cancer patients at Royal Papworth Hospital, undertaken instead of face-to-face consultations during the Covid-19 pandemic
|
Haslop, Claire
|
|
|
156 |
S1 |
p. S19
|
artikel
|
| 56 |
Factors predicting lung cancer in urgent cancer referrals
|
Ananth, Sachin
|
|
|
156 |
S1 |
p. S27
|
artikel
|
| 57 |
Fatigue in non-small cell lung cancer (NSCLC) patients treated with immunotherapy, is there a role for physical activity?
|
Calman, Lynn
|
|
|
156 |
S1 |
p. S48
|
artikel
|
| 58 |
Feasibility and convenience of immunotherapy at home for patients with cancer : a single-centre audit
|
Mohd Yusof, Harliana
|
|
|
156 |
S1 |
p. S41
|
artikel
|
| 59 |
Findings from a global survey of patient experience: Ireland, patient insights
|
Mc Namara, Aoife
|
|
|
156 |
S1 |
p. S51
|
artikel
|
| 60 |
Genetic mutations and signatures in lung cancer – findings from a whole exome sequencing platform
|
Dutta, Sanjay
|
|
|
156 |
S1 |
p. S1
|
artikel
|
| 61 |
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours
|
McDonald, Fiona
|
|
|
156 |
S1 |
p. S70-S71
|
artikel
|
| 62 |
High rates of radical treatment for stage III non-small cell lung cancer (NSCLC) at Barking, Havering & Redbridge University Hospitals NHS Trust (BHRUT)
|
Yasar, Binnaz
|
|
|
156 |
S1 |
p. S49-S50
|
artikel
|
| 63 |
Histological characteristics of screen-detected lung cancers: should rate of growth influence management?
|
Hall, Helen
|
|
|
156 |
S1 |
p. S71
|
artikel
|
| 64 |
Hodgkin lymphoma survivors’ attitudes towards lung cancer screening
|
Broadbent, Rachel
|
|
|
156 |
S1 |
p. S52-S53
|
artikel
|
| 65 |
How do we improve concurrent chemoradiotherapy rates in stage 3 NSCLC?
|
Smith, Fiona
|
|
|
156 |
S1 |
p. S61
|
artikel
|
| 66 |
How easy is it to read participant information about lung cancer screening?
|
Tonge, Janet
|
|
|
156 |
S1 |
p. S25-S26
|
artikel
|
| 67 |
Hypereosinophilia as a paraneoplastic syndrome in non-small cell carcinoma of the lung
|
Syed, Mohammad
|
|
|
156 |
S1 |
p. S76-S77
|
artikel
|
| 68 |
Identifying the need for Pneumocystis jivorecii pneumonia (PJP) prophylaxis in patients receiving radiotherapy for lung and mediastinal cancers – a single-institute analysis
|
Wong, Mei Yin
|
|
|
156 |
S1 |
p. S57-S58
|
artikel
|
| 69 |
Impact of COVID-19 on mesothelioma clinical nurse specialists
|
Taylor, Bethany
|
|
|
156 |
S1 |
p. S15-S16
|
artikel
|
| 70 |
Impact of the coronavirus pandemic and national lockdown on a lung cancer service – opportunities for innovation
|
Malhotra, Puneet
|
|
|
156 |
S1 |
p. S8
|
artikel
|
| 71 |
Impact of the Covid-19 pandemic on a District General Hospital EBUS service
|
Wright, Matthew
|
|
|
156 |
S1 |
p. S22-S23
|
artikel
|
| 72 |
Impact of the COVID-19 pandemic on the use of systemic anti-cancer therapy for patients diagnosed with malignancy at thoracoscopy in Aneurin Bevan University Health Board
|
Barton, Eleanor
|
|
|
156 |
S1 |
p. S11
|
artikel
|
| 73 |
Implementing a nurse-led downgrade clinic to reduce the lung cancer pathway
|
Anderson, Victoria
|
|
|
156 |
S1 |
p. S46-S47
|
artikel
|
| 74 |
Importance of support groups
|
Montague, Debra
|
|
|
156 |
S1 |
p. S52
|
artikel
|
| 75 |
Importance of the spleen as an OAR in left sided lung cancers: audit and recommendations
|
Hill, Nicola
|
|
|
156 |
S1 |
p. S59-S60
|
artikel
|
| 76 |
Improving the care of lung cancer patients of borderline fitness for surgery: a case study by the Accelerate, Coordinate and Evaluate Programme (ACE) programme
|
Palmer, Oliver
|
|
|
156 |
S1 |
p. S70
|
artikel
|
| 77 |
Incidence of T790M on progression based on first-line EGFR TKI therapy in the Midlands, UK
|
Powell, Rachel
|
|
|
156 |
S1 |
p. S44
|
artikel
|
| 78 |
Incidental findings and their budget impact in the South Tyneside and Sunderland low-dose CT lung cancer screening programme
|
Grover, Helen
|
|
|
156 |
S1 |
p. S25
|
artikel
|
| 79 |
Incidental PET-CT findings in a tertiary lung cancer referral centre: a retrospective analysis
|
Hiu Nian Chung, Jonathan
|
|
|
156 |
S1 |
p. S28-S29
|
artikel
|
| 80 |
Increased emergency presentation of new lung cancer diagnoses and less treatment: a COVID legacy
|
Julve, Maximilian
|
|
|
156 |
S1 |
p. S20
|
artikel
|
| 81 |
Initial findings of an international Delphi consensus study regarding the optimal management of radiation pneumonitis
|
Harrow, Stephen
|
|
|
156 |
S1 |
p. S64-S65
|
artikel
|
| 82 |
Interesting case of immunotherapy related pneumonitis presenting as radiation pneumonitis
|
Lowe, James
|
|
|
156 |
S1 |
p. S77-S78
|
artikel
|
| 83 |
Is MRI the superior test for investigating thymic pathologies in comparison to CT?
|
Donaldson, Eve
|
|
|
156 |
S1 |
p. S23
|
artikel
|
| 84 |
KRAS mutant lung adenocarcinomas (LAC):clinical spectrum and molecular profiling
|
Bulusu, Venkata
|
|
|
156 |
S1 |
p. S1-S2
|
artikel
|
| 85 |
Lung adenocarcinoma (LAC) with MET exon 14 skipping mutation treated with tepotinib: a case report
|
Bulusu, Venkata
|
|
|
156 |
S1 |
p. S75-S76
|
artikel
|
| 86 |
Lung cancer diagnosis: impact of the COVID-19 pandemic
|
Ali, Sohail
|
|
|
156 |
S1 |
p. S11
|
artikel
|
| 87 |
Lung cancer patients over 70 years on systemic anti-cancer therapy: experience within a local centre
|
Ridley, Francesca
|
|
|
156 |
S1 |
p. S44-S45
|
artikel
|
| 88 |
Lung cancer survival outcomes following LINAC based stereotactic radiosurgery/stereotactic radiotherapy (SRST) treatment of brain metastases: The Wessex Experience
|
Noble, Mark
|
|
|
156 |
S1 |
p. S62
|
artikel
|
| 89 |
Lung cancer treatment during a pandemic: how have multi-disciplinary teams changed?
|
Hargrave, James
|
|
|
156 |
S1 |
p. S18
|
artikel
|
| 90 |
Lung cancer upstaging due to the COVID-19 pandemic
|
Vella, Claire
|
|
|
156 |
S1 |
p. S10
|
artikel
|
| 91 |
Lung carcinoid tumours: analysis of changes in follow-up protocol in a single UK centre
|
Limbachia, Devan
|
|
|
156 |
S1 |
p. S4-S5
|
artikel
|
| 92 |
Lung nodule management in Covid-19: does postponed surveillance matter?
|
Ratnakumar, Ratnaprashanthika
|
|
|
156 |
S1 |
p. S19
|
artikel
|
| 93 |
Magnetic resonance-guided radiotherapy (MRgRT) for patients with lung cancer
|
Crockett, Cathryn
|
|
|
156 |
S1 |
p. S62
|
artikel
|
| 94 |
Maintaining flexible bronchoscopy and endobronchial ultrasound (EBUS) services during the COVID-19 pandemic at a tertiary centre: the Manchester Royal Infirmary experience
|
Nasr, Eman
|
|
|
156 |
S1 |
p. S7
|
artikel
|
| 95 |
Markers of efficacy in patients treated with immunotherapy for non-small cell lung cancer: a single cancer centre experience
|
Sallam, Mostafa
|
|
|
156 |
S1 |
p. S38-S39
|
artikel
|
| 96 |
Mesothelioma UK national mesothelioma audit
|
Aujayeb, Avinash
|
|
|
156 |
S1 |
p. S5-S6
|
artikel
|
| 97 |
MInimising radical RAdiotherapy Commencement time for Lung cancer to improve clinical outcomEs (MIRACLE)
|
Cheng, Joyce
|
|
|
156 |
S1 |
p. S57
|
artikel
|
| 98 |
Modern chemoradiation for lung cancer in Dorset. Real world experience with adjuvant durvalumab
|
Isola, Patrick
|
|
|
156 |
S1 |
p. S39-S40
|
artikel
|
| 99 |
Molecular testing in advanced non-small cell lung cancer: a 5-year review at an Irish tertiary referral centre
|
Doyle, Micheál
|
|
|
156 |
S1 |
p. S32-S33
|
artikel
|
| 100 |
Molecular testing in non-small cell lung cancer: a snapshot of The Royal Free London NHS Foundation Trust experience
|
Khalique, Saira
|
|
|
156 |
S1 |
p. S38
|
artikel
|
| 101 |
No evidence of increased susceptibility to COVID-19 virus among radical lung radiotherapy patients
|
Lepiarczyk, Oskar
|
|
|
156 |
S1 |
p. S9
|
artikel
|
| 102 |
Notes to authors
|
|
|
|
156 |
S1 |
p. S84
|
artikel
|
| 103 |
One-year experience of nurse-led standardised CT follow up for non-small cell lung cancer treated with surgery
|
Chung, Calvin
|
|
|
156 |
S1 |
p. S6
|
artikel
|
| 104 |
Outcome of patients with brain metastases ( BM ) from non-oncogene addicted non-small cell lung cancer ( NSCLC), treated with systemic anti-cancer therapy alone or in combination with local brain treatment. Experience from Portsmouth Oncology Centre
|
Gyi, Mya Mya
|
|
|
156 |
S1 |
p. S34-S35
|
artikel
|
| 105 |
Outcome of small cell lung cancer (SCLC) patients receiving palliative chemotherapy in a pan-Kent study
|
Shi, Jiaqi
|
|
|
156 |
S1 |
p. S65-S66
|
artikel
|
| 106 |
Outcome of surgery for non-small cell lung cancer with pathological N2 disease
|
Elsayed, Abdelrahman Elsayed
|
|
|
156 |
S1 |
p. S68-S69
|
artikel
|
| 107 |
Outcomes from a radical-intent treatment approach for patients with oligometastatic non-small cell lung carcinoma in a UK single-centre case series
|
Ajdarpasic, Denis
|
|
|
156 |
S1 |
p. S68
|
artikel
|
| 108 |
Outcomes of surveillance imaging for non-small cell lung cancer patients treated with curative-intent: a single-centre retrospective longitudinal study
|
Malins, Laura
|
|
|
156 |
S1 |
p. S54
|
artikel
|
| 109 |
Overall survival of stage III non-small cell lung cancer (NSCLC) in patients with good performance status at Barking, Havering & Redbridge University Hospitals NHS Trust (BHRUT)
|
Bloomfield, Adam
|
|
|
156 |
S1 |
p. S53
|
artikel
|
| 110 |
Palliative care provision in mesothelioma: perspectives of mesothelioma clinical nurse specialists in the UK
|
Gardiner, Clare
|
|
|
156 |
S1 |
p. S30-S31
|
artikel
|
| 111 |
Patient and informal carers experience of living with mesothelioma: a systematic rapid review and synthesis of the literature
|
Ejegi-Memeh, Stephanie
|
|
|
156 |
S1 |
p. S31
|
artikel
|
| 112 |
Patient and physician opinion of virtual care in the oncology department of an Irish tertiary care centre in the era of Covid-19
|
O’Reilly, Mary
|
|
|
156 |
S1 |
p. S12
|
artikel
|
| 113 |
Patient survey to identify the outcome of the information given regarding lung cancer diagnosis and treatment
|
Booth, Sarah
|
|
|
156 |
S1 |
p. S48-S49
|
artikel
|
| 114 |
PDL-1 assessment – how does it affect lung cancer management? A service evaluation
|
Eng, Cindy
|
|
|
156 |
S1 |
p. S42
|
artikel
|
| 115 |
Peripheral eosinophilia in long-term survivors with NSCLC under immunotherapy with ICIs: presentation of two cases and review of literature
|
Chrysanthidis, Miltiadis
|
|
|
156 |
S1 |
p. S75
|
artikel
|
| 116 |
Physician performed US guided pleural biopsies in thoracic malignancy
|
Sundaralingam, Anand
|
|
|
156 |
S1 |
p. S28
|
artikel
|
| 117 |
Plasma cell-free DNA EGFR mutation detection in patients with non-small cell lung carcinoma using two commercially available platforms the COBAS® and Idylla™
|
O’Callaghan, Marissa
|
|
|
156 |
S1 |
p. S21
|
artikel
|
| 118 |
Pleomorphic lung carcinoma – a rare response to a rare tumour
|
Clark, James
|
|
|
156 |
S1 |
p. S76
|
artikel
|
| 119 |
Pneumomediastinum, lung cancer and Covid-19
|
Aujayeb, Avinash
|
|
|
156 |
S1 |
p. S73
|
artikel
|
| 120 |
Posterior reversible encephalopathy syndrome (PRES) presenting as intractable vomiting in a patient with metastatic small cell lung cancer on chemo-immunotherapy
|
Wood, Katie
|
|
|
156 |
S1 |
p. S77
|
artikel
|
| 121 |
Precision thoracic oncology in the UK: a two-step NGS pathway for extended molecular profiling in NSCLC
|
Moore, David
|
|
|
156 |
S1 |
p. S45-S46
|
artikel
|
| 122 |
Pre-treatment serum albumin is a prognostic biomarker for locally advanced non-small cell lung cancer: extended follow up of patients treated with concurrent chemo-radiotherapy
|
Killean, Angus
|
|
|
156 |
S1 |
p. S3-S4
|
artikel
|
| 123 |
Prevalence, treatment and outcomes of patients with advanced, non-squamous NSCLC (nsNSCLC) harbouring ALK or ROS1 gene-rearrangements in Dorset
|
Hack, Joanna
|
|
|
156 |
S1 |
p. S36-S37
|
artikel
|
| 124 |
Prognostic factors for control of early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
|
Charlton, Thomas
|
|
|
156 |
S1 |
p. S60-S61
|
artikel
|
| 125 |
Programmed death-ligand (PD-L1) expression and tissue heterogeneity in advanced non-small cell lung cancer (NSCLC)
|
Decatris, Marios
|
|
|
156 |
S1 |
p. S29-S30
|
artikel
|
| 126 |
Quantifying the impact of Covid-19 on lung cancer: an urgent need for restoration
|
O’Dowd, Emma
|
|
|
156 |
S1 |
p. S15
|
artikel
|
| 127 |
Radical (chemo)radiotherapy for NSCLC, overall survival data from the South West Wales Cancer Centre (SWWCC)
|
Barrington, Craig
|
|
|
156 |
S1 |
p. S58
|
artikel
|
| 128 |
Radical radiotherapy in stage III NSCLC – why not chemoradiotherapy?
|
Smith, Eleanor
|
|
|
156 |
S1 |
p. S63-S64
|
artikel
|
| 129 |
Real-world-outcomes for ALK positive advanced NSCLC patients treated in South Yorkshire
|
Sheehan, Roseleen
|
|
|
156 |
S1 |
p. S39
|
artikel
|
| 130 |
Real world outcomes in patients with lung oligometastases treated with SABR – a single-centre experience
|
Fatimilehin, Abiola
|
|
|
156 |
S1 |
p. S58-S59
|
artikel
|
| 131 |
Real-world outcomes using pembrolizumab plus pemetrexed-platinum in 1st line metastatic NSCLC compared to results reported from KEYNOTE-189: a multicentre experience
|
Ravindra, Saranya
|
|
|
156 |
S1 |
p. S46
|
artikel
|
| 132 |
Real world prospective data on tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor mutation positive non-small cell lung cancer at the Edinburgh Cancer Centre
|
Swan, Amanda
|
|
|
156 |
S1 |
p. S32
|
artikel
|
| 133 |
Real-world safety and efficacy of immune-checkpoint inhibitors (ICIs) in the elderly NSCLC population of a UK tertiary centre
|
Lopez Escola, Cristina
|
|
|
156 |
S1 |
p. S40-S41
|
artikel
|
| 134 |
Real world treatment outcomes for lung cancer patients 85 year and older diagnosed through direct to CT pathway
|
Parvez, Wadood
|
|
|
156 |
S1 |
p. S50-S51
|
artikel
|
| 135 |
Retrospective study to compare the dosimetric difference on treatment volume (PTV) and lung V20 in patients receiving lung stereotactic ablative radiotherapy (SABR) based on use of abdominal compression
|
Mokhtar, Nur Adila Mokhtar
|
|
|
156 |
S1 |
p. S64
|
artikel
|
| 136 |
Reviewing the diagnostic pathway in lung cancer patients with best supportive care decisions – are there lessons to be learnt?
|
King, Jenny
|
|
|
156 |
S1 |
p. S66
|
artikel
|
| 137 |
Review of the work-up for patients diagnosed with malignant pleural mesothelioma in Northern Ireland 2019–2020
|
Burke, David
|
|
|
156 |
S1 |
p. S30
|
artikel
|
| 138 |
Role of lung function in predicting risk of iatrogenic pneumothorax post CT-guided lung biopsy
|
Shoaib, Bilal
|
|
|
156 |
S1 |
p. S22
|
artikel
|
| 139 |
Routine electronic patient reported outcomes measures (ePROMs) for patients with lung cancer
|
Crockett, Cathryn
|
|
|
156 |
S1 |
p. S6
|
artikel
|
| 140 |
Sarcopenia is not a useful prognostic biomarker in metastatic NSCLC patients treated with first-line pembrolizumab
|
Thomson, Findlay
|
|
|
156 |
S1 |
p. S42
|
artikel
|
| 141 |
Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer
|
Ding, Tze-en Grace
|
|
|
156 |
S1 |
p. S43
|
artikel
|
| 142 |
Segmentectomy outcomes at the Golden Jubilee National Hospital: a retrospective analysis
|
Tan, Dylan
|
|
|
156 |
S1 |
p. S69
|
artikel
|
| 143 |
Sequential chemo radiation (SCRT) in locally advanced NSCLC: a review of outcomes in a single institution practice
|
Kota, Vamsi
|
|
|
156 |
S1 |
p. S55-S56
|
artikel
|
| 144 |
Should patients with an unknown smoking status be routinely invited for targeted lung health check?
|
Gourlay, Ewan
|
|
|
156 |
S1 |
p. S24
|
artikel
|
| 145 |
Six versus three-weekly pembrolizumab: as well-tolerated?
|
Williams, Fiona
|
|
|
156 |
S1 |
p. S11-S12
|
artikel
|
| 146 |
Stereotactic ablative body radiotherapy (SABR) lung fractionations locally in the COVID-19 era and the impact on dosimetry, resources, early toxicities, and the environment
|
Phelps, Lyndsey
|
|
|
156 |
S1 |
p. S59
|
artikel
|
| 147 |
Stereotactic ablative radiotherapy (SABR) for primary lung malignancy: a regional analysis of survival and recurrence outcomes amongst an elderly cohort
|
Nicholas, Terese
|
|
|
156 |
S1 |
p. S61-S62
|
artikel
|
| 148 |
Surveillance after surgical resection of lung cancer – would the LNC-PATH risk stratification score affect follow-up protocols in Royal Glamorgan Hospital?
|
Landstrom, Hannah
|
|
|
156 |
S1 |
p. S68
|
artikel
|
| 149 |
Surveillance brain imaging in oncogene-driven non-small cell lung cancer: The Kent Oncology Centre experience
|
Tippu, Zayd
|
|
|
156 |
S1 |
p. S21-S22
|
artikel
|
| 150 |
Survival outcomes following concomitant chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC) at Oxford University Hospitals (OUH) NHS Trust
|
Johnstone, Philippa
|
|
|
156 |
S1 |
p. S36
|
artikel
|
| 151 |
Survival outcomes for NSCLC patients following palliative radiotherapy in Velindre Cancer Centre
|
Barrington, Craig
|
|
|
156 |
S1 |
p. S58
|
artikel
|
| 152 |
Systematic review of neoadjuvant immunotherapy for patients with non-small cell lung cancer
|
Le, Anthony
|
|
|
156 |
S1 |
p. S32
|
artikel
|
| 153 |
The clinical utility of Guardant360 in directing management of NSCLC patients – a small cohort study
|
Shi, Jiaqi
|
|
|
156 |
S1 |
p. S4
|
artikel
|
| 154 |
The delay between staging PET and resection of lung cancer – does extra theatre capacity make a difference?
|
Purmessur, Rushmi
|
|
|
156 |
S1 |
p. S67-S68
|
artikel
|
| 155 |
The effect of COVID-19 on the presentation, staging, and treatment of lung cancer: a retrospective comparative audit of the ‘first wave’
|
Evetts, Lisa
|
|
|
156 |
S1 |
p. S10-S11
|
artikel
|
| 156 |
The effects of the COVID-19 pandemic on the lung cancer service at Northwick Park Hospital (NWPH)
|
Anandan, Lavanya
|
|
|
156 |
S1 |
p. S9-S10
|
artikel
|
| 157 |
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)
|
Kulasinghe, Arutha
|
|
|
156 |
S1 |
p. S1
|
artikel
|
| 158 |
The impact of a smoking cessation intervention in the Wakefield lung health check pilot
|
Kingsbury, Amanda
|
|
|
156 |
S1 |
p. S54
|
artikel
|
| 159 |
The impact of COVID-19 on lung cancer diagnostics – a multicentre comparison of 2019/2020 data
|
Navani, Neal
|
|
|
156 |
S1 |
p. S19-S20
|
artikel
|
| 160 |
The impact of ‘day zero’ image verification sessions for patients receiving lung stereotactic ablative radiotherapy: a single institution audit
|
Pang, Jennifer
|
|
|
156 |
S1 |
p. S64
|
artikel
|
| 161 |
The impact of SARS-COV-2 pandemic on pleural services, diagnosis of malignant effusions and junior doctors’ procedural training
|
Riddell, Nathan
|
|
|
156 |
S1 |
p. S13
|
artikel
|
| 162 |
The impact of the COVID-19 pandemic on lung cancer diagnosis and stage at Plymouth NHS Trust
|
McDill, Helen
|
|
|
156 |
S1 |
p. S17
|
artikel
|
| 163 |
The impact of the COVID-19 pandemic on patient advocacy and support organisations in the UK and Ireland – results from a Global Lung Cancer Coalition (GLCC) survey
|
Dallas, Lorraine
|
|
|
156 |
S1 |
p. S9
|
artikel
|
| 164 |
The impact of the COVID-19 pandemic on pleural activity at Plymouth NHS Trust
|
McDill, Helen
|
|
|
156 |
S1 |
p. S16-S17
|
artikel
|
| 165 |
The impact of the COVID-19 pandemic on referrals and diagnoses of lung cancer in a tertiary hospital
|
Arberry, Jamie
|
|
|
156 |
S1 |
p. S14-S15
|
artikel
|
| 166 |
The integration of occupational therapy at the point of diagnosis in lung cancer
|
Evans, Nicola
|
|
|
156 |
S1 |
p. S47-S48
|
artikel
|
| 167 |
The invaluable introduction of a cancer care co-ordinator into the lung cancer team
|
Anderson, Victoria
|
|
|
156 |
S1 |
p. S47
|
artikel
|
| 168 |
The pleural vent can be used in pneumothorax after CT-guided lung biopsy
|
Bain, Lewis
|
|
|
156 |
S1 |
p. S22
|
artikel
|
| 169 |
The role of the immune microenvironment in EGFR mutant NSCLC
|
Monkman, James
|
|
|
156 |
S1 |
p. S2-S3
|
artikel
|
| 170 |
The survival outcomes of patients with lung cancer managed as best supportive care
|
Cheng, LokYin
|
|
|
156 |
S1 |
p. S67
|
artikel
|
| 171 |
The use of PLCOm2012 vs PLCOm2012noRace risk prediction models in a UK lung cancer screening programme
|
Bradley, Patrick
|
|
|
156 |
S1 |
p. S25
|
artikel
|
| 172 |
The use of video consultations in the lung cancer fast track clinic: patients’ feedback
|
Kenworthy, Jill
|
|
|
156 |
S1 |
p. S47
|
artikel
|
| 173 |
Title Page
|
|
|
|
156 |
S1 |
p. i
|
artikel
|
| 174 |
To tri or not to tri: a single-centre experience of upfront tri-modality treatment for non-small cell lung cancer
|
Little, Jessica
|
|
|
156 |
S1 |
p. S60
|
artikel
|
| 175 |
Treatment dose-delay due to an exercise induced creatinine kinase level elevation/raise in a man with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (aNSCLC) – a case report
|
Sandsund, Catherine
|
|
|
156 |
S1 |
p. S75
|
artikel
|
| 176 |
Ultrasound guided neck node aspiration cytology in patients with lung cancer
|
Khan, Kashif Ali
|
|
|
156 |
S1 |
p. S29
|
artikel
|
| 177 |
Uncertain resection margins and patterns of recurrence following the surgical resection of non-small cell lung cancer
|
Scholes, Hannah
|
|
|
156 |
S1 |
p. S69-S70
|
artikel
|
| 178 |
Understanding patient experience: findings for Ireland and the UK and from the first Global Lung Cancer Coalition Patient Experience Survey
|
Beattie, Vanessa
|
|
|
156 |
S1 |
p. S52
|
artikel
|
| 179 |
Uptake and outcomes of adjuvant durvalumab following concurrent chemoradiotherapy in unresected stage 3 non-small-cell lung cancer
|
Mason, Holly
|
|
|
156 |
S1 |
p. S41
|
artikel
|
| 180 |
Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
|
Sen, Rebecca
|
|
|
156 |
S1 |
p. S18
|
artikel
|
| 181 |
Use of the Biosentry tract sealant system (Angiodynamics®) for radiological marking of lung lesions as an adjunct to surgery
|
Maddock, Mark
|
|
|
156 |
S1 |
p. S73
|
artikel
|
| 182 |
Using the CARG prediction score to influence patient decision to proceed with chemotherapy based on the predicted incidence of toxicity in lung cancer
|
Baker, Harriet
|
|
|
156 |
S1 |
p. S45
|
artikel
|
| 183 |
USO1 in non-small cell lung cancer
|
Keogh, Anna
|
|
|
156 |
S1 |
p. S2
|
artikel
|
| 184 |
Vertebral compression fractures (VCF) an important risk factor in concurrent chemoradiotherapy (CRT) of stage II/ III lung cancer
|
Choudhury, Mahbuba
|
|
|
156 |
S1 |
p. S74-S75
|
artikel
|
| 185 |
What do we do with chest X-rays which are abnormal but not suspicious for lung cancer? Still a role for direct recall CT
|
Perry-Thomas, Robyn
|
|
|
156 |
S1 |
p. S6-S7
|
artikel
|
| 186 |
What proportion of patients staged as single station N2 with pre-operative EBUS-TBNA have multi-station N2 from intra-operative lymph node staging?
|
Craig, Christopher
|
|
|
156 |
S1 |
p. S23
|
artikel
|
| 187 |
“Why I exercise while being treated for mesothelioma” – a case report from the patient’s perspective
|
Bouscarle, Paul
|
|
|
156 |
S1 |
p. S72-S73
|
artikel
|
| 188 |
10 years clinical outcome of TKIs in EGFR-mutant advanced NSCLC – UHNM experience
|
Elmasry, Abdelfattah
|
|
|
156 |
S1 |
p. S33-S34
|
artikel
|
| 189 |
5 years of indwelling pleural catheters in a DGH
|
Aujayeb, Avinash
|
|
|
156 |
S1 |
p. S67
|
artikel
|
| 190 |
10 years of medical thoracoscopy in a DGH
|
Aujayeb, Avinash
|
|
|
156 |
S1 |
p. S27-S28
|
artikel
|
| 191 |
‘Your cough could be masking something else’ – raising awareness of lung cancer during the Covid-19 pandemic
|
Mc Namara, Aoife
|
|
|
156 |
S1 |
p. S7
|
artikel
|
Tijdschrift beschrijving